Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

J Pediatric Infect Dis Soc. 2024 Feb 26;13(2):144-147. doi: 10.1093/jpids/piad113.

Abstract

To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients. Clinical Trial Registration: Clinicaltrials.gov, NCT03979313, https://clinicaltrials.gov/ct2/show/NCT03979313.

Keywords: immunization; monoclonal antibody; nirsevimab; respiratory syncytial virus.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Child
  • Humans
  • Infant
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus, Human*
  • Respiratory Tract Infections* / drug therapy
  • Respiratory Tract Infections* / prevention & control
  • Seasons

Substances

  • Antibodies, Monoclonal, Humanized
  • nirsevimab

Associated data

  • ClinicalTrials.gov/NCT03979313

Grants and funding